{
    "clinical_study": {
        "@rank": "79081", 
        "arm_group": [
            {
                "arm_group_label": "Triptorelin", 
                "arm_group_type": "Active Comparator", 
                "description": "Triptorelin 22,5mg/24th week intramuscularly"
            }, 
            {
                "arm_group_label": "orchiectomy", 
                "arm_group_type": "Active Comparator", 
                "description": "Androgen deprivation therapy by bilateral subcapsular orchiectomy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate if androgen deprivation therapy in men with\n      prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat\n      distribution."
        }, 
        "brief_title": "MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostate Cancer", 
            "Metabolic Syndrome", 
            "Hypogonadism", 
            "Fatty Liver"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Hypogonadism", 
                "Prostatic Neoplasms", 
                "Metabolic Syndrome X"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a substudy of the ongoing randomized trial entitled: Metabolic Changes Due to\n      Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin\n      (EudraCT number: 2013-002553-29). 20 consecutive patients are anticipated to participate\n      regardless of assignment to either orchiectomy or triptorelin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible for inclusion are patients who are included in the already ongoing\n             Randomised trial entitled: Metabolic Changes Due to Iatrogenic Hypogonadism in\n             Patients With Prostate Cancer: Orchiectomy vs. Triptorelin  (EudraCT number:\n             2013-002553-29)\n\n        Exclusion Criteria:\n\n          -  Implanted devices or foreign metallic bodies incompatible with Magnetic Resonance\n             Imaging.\n\n          -  claustrophobia\n\n          -  Severe Psychiatric disease"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102646", 
            "org_study_id": "kk2013 MRI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Triptorelin", 
                "description": "Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.", 
                "intervention_name": "Triptorelin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Triptorelin", 
                    "Pamorelin"
                ]
            }, 
            {
                "arm_group_label": "orchiectomy", 
                "description": "Androgen deprivation therapy by bilateral subcapsular orchiectomy", 
                "intervention_name": "Orchiectomy", 
                "intervention_type": "Procedure", 
                "other_name": "Subcapsular orchiectomy"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Triptorelin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Herlev", 
                    "country": "Denmark", 
                    "zip": "2730"
                }, 
                "name": "Herlev Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Peter B \u00d8stergren, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Elizaveta Chabanova, Physicist", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Caroline M Kistorp, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mikkel Fode, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jens S\u00f8nksen, Prof., DMSc.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin", 
        "overall_contact": {
            "email": "peter.busch.oestergren@regionh.dk", 
            "last_name": "Peter B \u00d8stergren, MD", 
            "phone": "(+45) 38 68 15 05"
        }, 
        "overall_official": {
            "affiliation": "Department of Urology, Herlev Hospital, Denmark", 
            "last_name": "Peter B \u00d8stergren, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in hepatic fat content measured by Magnetic Resonance Spectroscopy", 
            "measure": "Change in hepatic fat content", 
            "safety_issue": "No", 
            "time_frame": "At baseline (within 4 weeks of commencement of androgen deprivation therapy) and after 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102646"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Herlev Hospital", 
            "investigator_full_name": "Peter Busch \u00d8stergren", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in visceral and subcutaneous fat mass measured by Magnetic Resonance Imaging.", 
                "measure": "Change in visceral/subcutaneous fat mass", 
                "safety_issue": "No", 
                "time_frame": "At baseline (within 4 weeks of commencement of androgen deprivation therapy) and after 24 weeks"
            }, 
            {
                "description": "To investigate possible correlation between androgen status before commencing androgen deprivation therapy and hepatic fat content at baseline.", 
                "measure": "Correlation between Hepatic fat content and baseline androgen status", 
                "safety_issue": "No", 
                "time_frame": "Androgen status measured before commencement of androgen deprivation therapy (ADT), hepatic fat content measured at baseline (within 1 month of commencing androgen deprivation therapy)"
            }
        ], 
        "source": "Herlev Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Herlev Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}